Frontiers: University of Kansas Clinical and Translational Science Institute

前沿:堪萨斯大学临床与转化科学研究所

基本信息

  • 批准号:
    9560956
  • 负责人:
  • 金额:
    $ 402.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-07 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

Contact PD/PI: Barohn, Richard Joel OVERALL: ABSTRACT Frontiers: The Heartland Institute for Clinical and Translational Research has been a catalyst for bringing together translational science investigators and stakeholders across the KC region, and beyond. Located at the University of Kansas Medical Center (KUMC) under the leadership of Dr. Barohn, our commitment to team science and multidisciplinary collaboration reaches beyond the walls of our academic health science center and promotes collaboration among investigators from diverse disciplines across local partner academic institutions and affiliated health care institutions. The vision of Frontiers is to contribute to and lead national efforts to transform the way we do clinical and translational research (CTR), and to ensure research is more rapidly and more efficiently translated to the point of care so that it may contribute to improved health. Specifically, Frontiers aims to: 1) Engage in bi-directional collaboration with all stakeholders to develop, demonstrate, and disseminate advances across the translational science spectrum that insures inclusion and integration of complex and diverse populations and individuals across the lifespan from birth to end of life; 2) Create a sustainable translational workforce of multi-disciplinary investigators, research personnel, and community and patient stakeholders in the use of translational science tools through innovative and creative programs; and 3) Strengthen institutional and regional infrastructure to accelerate translational research. We will accomplish these aims by drawing on our considerable strengths: a) developing informatics tools for making EHR data `research ready' and implementing clinic- and community-based registries for study recruitment and other translational research applications; b) nurturing and sustaining strong patient and community engagement relationships that will support research with African American, Latino, American Indian, LGBTQ, pediatric, geriatric, rare disease, prison, and rural populations; c) offering innovative training programs for the entire CTR workforce (not just investigators), including plans for comprehensive entrepreneurship and implementation research training and creating new team science brainstorming mechanisms that will lead to multidisciplinary discovery projects and d) advancing medical devices and re-purposed drugs to patients through novel strategies developed by Frontiers' Institute for Advancing Medical Innovations (IAMI)that is nationally known for its product development translational research and high impact collaborations with industry, academia, government, and disease philanthropy partners. All Frontiers units are linked by a group of Navigators that can be accessed by Frontiers investigative teams and community partners. These plans position Frontiers to contribute to goals, and lead initiatives of the CTSA network by building on technological, computational, and health/disease knowledge to advance translational research. Project Summary/Abstract Page 274 Contact PD/PI: Barohn, Richard Joel OVERALL NARRATIVE Frontiers: The Heartland Institute for Clinical and Translational Research provides infrastructure and educational programs to develop the next generation of CTR investigative teams. As a regional organization involving two states and three universities, Frontiers is able to blend the best resources available to advance team, community and clinical translational science. This results in accelerating discoveries and research findings that may be more rapidly brought to the point of care and contribute to population health.
联系PD/PI:Barohn,Richard Joel 总体:摘要 前沿:哈特兰临床和转化研究所一直是推动 将翻译科学研究人员和KC地区乃至更远地区的利益相关者聚集在一起。设于 在巴罗恩博士领导的堪萨斯大学医学中心(KUMC),我们的承诺 团队科学和多学科合作超越了我们学术健康的界限 科学中心,并促进来自不同学科的研究人员在当地 合作学术机构和附属医疗保健机构。前沿的愿景是贡献 并领导国家努力转变我们进行临床和转化研究(CTR)的方式,并 确保更快、更有效地将研究转化为关注点,以便它可以做出贡献 为了改善健康。具体来说,Frontiers的目标是:1)与所有 利益相关者在翻译科学领域开发、演示和传播进展 确保将复杂和多样化的人群和个人纳入和整合的范围 从出生到生命终结的生命周期;2)创建一支可持续的多学科翻译队伍 研究人员、研究人员、社区和患者利益相关者使用翻译 通过创新和创造性方案提供科学工具;以及3)加强机构和区域 加快翻译研究的基础设施。我们将利用我们的资源来实现这些目标 相当大的优势:a)开发信息学工具,使电子病历数据“随时可供研究”; 为研究招募和其他转化性研究实施诊所和社区登记 应用程序;b)培养和维持牢固的患者和社区参与关系, 支持非洲裔美国人、拉丁裔美国人、美国印第安人、LGBTQ、儿科、老年科、罕见的研究 疾病、监狱和农村人口;c)为整个CTR提供创新的培训方案 工作人员(不仅仅是调查人员),包括全面创业和实施计划 研究、培训和创建新的团队科学集思广益机制,将导致 多学科发现项目和d)向患者推广医疗设备和重新调整用途的药物 通过前沿医疗创新研究所(IAMI)开发的新战略,即 以其产品开发、翻译研究和与 工业界、学术界、政府和疾病慈善机构的合作伙伴。所有边防单位都由一个 可由Frontiers调查团队和社区合作伙伴访问的导航员组。 这些计划使Frontiers能够为实现目标做出贡献,并通过建立 关于技术、计算和健康/疾病的知识,以促进翻译研究。 项目摘要/摘要页274 联系PD/PI:Barohn,Richard Joel 整体叙事 前沿:哈特兰临床和转化研究所提供基础设施和 发展下一代CTR调查团队的教育方案。作为地区性组织 涉及两个州和三所大学的Frontiers能够融合可用的最佳资源来推进 团队、社区和临床转化科学。这加快了发现和研究的速度 这些发现可能会更快地被带到关注点,并有助于人口健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard J. Barohn其他文献

<strong>NEO1 and NEO-EXT studies: Long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in late-onset Pompe disease patients</strong>
  • DOI:
    10.1016/j.ymgme.2019.11.107
  • 发表时间:
    2020-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mazen M. Dimachkie;Richard J. Barohn;Barry Byrne;Ozlem Goker-Alpan;Priya S. Kishnani;Shafeeq Ladha;Pascal Laforêt;Karl Eugen Mengel;Loren D.M. Pena;Sabrina Sacconi;Volker Straub;Jaya Trivedi;Philip Van Damme;Ans van der Ploeg;John Vissing;Peter Young;Kristina An Haack;Carmen Fleurinck;Judith Johnson;Kejian Liu
  • 通讯作者:
    Kejian Liu
Congenital Myasthenic Syndromes: a Clinical and Treatment Approach
  • DOI:
    10.1007/s11940-018-0520-7
  • 发表时间:
    2018-07-21
  • 期刊:
  • 影响因子:
    1.800
  • 作者:
    Constantine Farmakidis;Mamatha Pasnoor;Richard J. Barohn;Mazen M. Dimachkie
  • 通讯作者:
    Mazen M. Dimachkie
<strong>NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset pompe disease (LOPD)</strong>
  • DOI:
    10.1016/j.ymgme.2020.12.064
  • 发表时间:
    2021-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mazen M. Dimachkie;Richard J. Barohn;Barry Byrne;Ozlem Goker-Alpan;Priya S. Kishnani;Shafeeq Ladha;Pascal Laforêt;Karl Eugen Mengel;Loren D.M. Pena;Sabrina Sacconi;Volker Straub;Jaya Trivedi;Philip Van Damme;Ans van der Ploeg;John Vissing;Peter Young;Kristina An Haack;Inna Ivanina;Xiaoyu Lu; Benedikt Schoser; on behalf of NEO-EXT investigators
  • 通讯作者:
    Benedikt Schoser; on behalf of NEO-EXT investigators
Painful peripheral neuropathy
  • DOI:
    10.1007/s11940-002-0034-0
  • 发表时间:
    2002-05-01
  • 期刊:
  • 影响因子:
    1.800
  • 作者:
    Gil I. Wolfe;Richard J. Barohn
  • 通讯作者:
    Richard J. Barohn

Richard J. Barohn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard J. Barohn', 18)}}的其他基金

Frontiers: University of Kansas Clinical and Translational Science Institute
前沿:堪萨斯大学临床与转化科学研究所
  • 批准号:
    9514338
  • 财政年份:
    2017
  • 资助金额:
    $ 402.38万
  • 项目类别:
Models of Neuromuscular Disease Across the Lifespan
整个生命周期的神经肌肉疾病模型
  • 批准号:
    9195818
  • 财政年份:
    2016
  • 资助金额:
    $ 402.38万
  • 项目类别:
A Phase II Trial of Rituximab In Myasthenia Gravis
利妥昔单抗治疗重症肌无力的 II 期试验
  • 批准号:
    8644497
  • 财政年份:
    2013
  • 资助金额:
    $ 402.38万
  • 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
  • 批准号:
    8569903
  • 财政年份:
    2013
  • 资助金额:
    $ 402.38万
  • 项目类别:
A Phase II Trial of Rituximab In Myasthenia Gravis
利妥昔单抗治疗重症肌无力的 II 期试验
  • 批准号:
    8731286
  • 财政年份:
    2013
  • 资助金额:
    $ 402.38万
  • 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
  • 批准号:
    8683099
  • 财政年份:
    2013
  • 资助金额:
    $ 402.38万
  • 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
  • 批准号:
    9341908
  • 财政年份:
    2013
  • 资助金额:
    $ 402.38万
  • 项目类别:
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
美金刚治疗肌萎缩侧索硬化症的 2B 期试验
  • 批准号:
    10242456
  • 财政年份:
    2013
  • 资助金额:
    $ 402.38万
  • 项目类别:
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis
雷沙吉兰治疗肌萎缩侧索硬化症的 2 期研究
  • 批准号:
    8355588
  • 财政年份:
    2012
  • 资助金额:
    $ 402.38万
  • 项目类别:
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis
雷沙吉兰治疗肌萎缩侧索硬化症的 2 期研究
  • 批准号:
    8543461
  • 财政年份:
    2012
  • 资助金额:
    $ 402.38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 402.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了